Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Identifying post-transplant secondary pulmonary infections

Michael Boeckh • 28 Oct 2022
COSTEM 2022
General

Michael Boeckh, MD, PhD, Fred Hutchinson Cancer Research Center, Washington, WA, discusses various secondary respiratory tract infections patients may receive after stem cell transplantation, especially in immunocompromised individuals. Infections such as respiratory syncytial virus (RSV), human metapneumovirus and parainfluenza viruses may negatively affect outcomes and Dr Boeckh highlights research in the epidemiology and management of these diseases, as well as how the immune system controls infection. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Boeckh

Letermovir prophylaxis to prevent infection after HSCT
1:17
Letermovir prophylaxis to prevent infection after HSCT
Michael Boeckh • 28 Oct 2022

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals